Use of FibroScan in Liver Disease Diagnosis

Primary Indications by Disease Category

• The European Association for the Study of the Liver recommends calculating FIB-4 first in all adults with Non-Alcoholic Fatty Liver Disease (NAFLD) using routine labs (AST, ALT, platelet count, age) 1, 2
• FibroScan cutoff <8 kPa reliably rules out advanced fibrosis in patients with alcohol-related liver disease 2
• The American Association for the Study of Liver Diseases recommends ordering FibroScan for staging fibrosis in patients with confirmed chronic hepatitis B or C to guide treatment decisions 3, 4
• Use APRI score >0.5 or FibroScan >7.0 kPa to identify significant fibrosis (≥F2) in patients with chronic hepatitis B or C 3
• Use APRI score >1.0 or FibroScan >12.5 kPa to identify cirrhosis in patients with chronic hepatitis B or C 3
• FibroScan has sensitivity/specificity of 70%/84% for significant fibrosis and 87%/91% for cirrhosis in viral hepatitis 5

Populations Where FibroScan Should Be Used

• The European Association for the Study of the Liver recommends ordering FibroScan in patients at risk of advanced liver fibrosis, including those with metabolic risk factors (obesity, diabetes, metabolic syndrome) 1, 2
• Patients with harmful alcohol use should be considered for FibroScan 1
• Patients with confirmed chronic viral hepatitis should be considered for FibroScan 3, 4
• Patients with persistently elevated liver enzymes of unclear etiology should be considered for FibroScan 1

Technical Validity Requirements

• A FibroScan result is only reliable if it meets all three criteria: ≥10 successful measurements obtained, success rate ≥60%, and interquartile range <30% of median value 4
• The American College of Radiology recommends considering the technical validity requirements for FibroScan results 5

Interpretation Thresholds for Clinical Decision-Making

• The Lancet Gastroenterology and Hepatology recommends that a FibroScan result of >12.5 kPa indicates cirrhosis and requires urgent hepatology referral and HCC screening 3
• A FibroScan cutoff <8.0 kPa rules out advanced fibrosis in patients with alcohol-related liver disease 2

Common Pitfalls to Avoid

• The American Association for the Study of Liver Diseases recommends ensuring ALT, AST, and platelet count are part of routine investigations so simple non-invasive scores can be calculated before ordering FibroScan 1, 2
• The American Gastroenterological Association recommends not relying on FibroScan alone to rule out other causes of liver disease, as it only measures stiffness, not inflammation or alternative diagnoses 4

FibroScan Guidelines for Liver Disease Assessment

Clinical Scenarios Requiring FibroScan

• The British Society of Gastroenterology recommends using FibroScan as a second-line test after initial risk stratification with FIB-4 or NAFLD Fibrosis Score shows indeterminate or elevated results, or as a first-line assessment in patients drinking at harmful levels (≥35 units/week for women, ≥50 units/week for men) 6, 7
• For Non-Alcoholic Fatty Liver Disease (NAFLD), the European Association for the Study of the Liver suggests a stepwise approach starting with simple blood tests, calculating FIB-4 or NAFLD Fibrosis Score in all adults with NAFLD, and using FibroScan for patients with indeterminate scores (FIB-4 1.3-3.25 or NFS -1.455 to 0.675) 6, 7, 8
• The American Association for the Study of Liver Diseases recommends referring high-risk patients (FIB-4 >3.25 or NFS >0.675) to hepatology regardless of FibroScan results, and using FibroScan to assess fibrosis in patients with indeterminate scores 6, 8
• For alcohol-related liver disease, FibroScan is indicated earlier in the diagnostic pathway, with immediate assessment recommended for patients drinking at harmful levels (≥35 units/week for women, ≥50 units/week for men) 6, 7, 8

Critical Timing Considerations

• The European Association for the Study of the Liver advises avoiding FibroScan during active inflammation or recent alcohol use, as recent alcohol consumption can falsely elevate liver stiffness measurements, and ideally performing the test after 2 weeks of abstinence 9

Follow-Up FibroScan Timing

• The British Society of Gastroenterology recommends repeat testing intervals depending on initial findings, with patients with low-risk scores and FibroScan <7.8 kPa repeating the pathway in 3-5 years if risk factors remain 6, 7

Important Limitations and Pitfalls

• The American Association for the Study of Liver Diseases notes that FibroScan has technical limitations, including failed acquisition in obese patients, and requires ≥10 successful measurements with a success rate ≥60% and interquartile range <30% of median value for reliability 10

When FibroScan Provides Prognostic Value

• The European Association for the Study of the Liver suggests that FibroScan provides critical prognostic information to prioritize follow-up urgency, particularly for patients with limited healthcare access 9

FibroScan Procedure and Interpretation

Patient Preparation and Technical Procedure

• The American Association for the Study of Liver Diseases recommends that patients fast for at least 4 hours before the examination, as food intake increases hepatic blood flow and can falsely elevate liver stiffness measurements 11
• The patient should lie supine with the right arm raised in maximal abduction to widen the intercostal spaces, and the ultrasound probe is positioned on the right upper abdomen over the right lobe of the liver through the intercostal space 11
• Measurements are taken at a depth of 1.5-2 cm below the liver capsule, avoiding measurements <1 cm depth due to reverberation artifacts, and the patient briefly holds their breath during each measurement 11
• The device generates a mechanical vibration that creates shear waves, and measures liver stiffness by calculating the velocity of these shear waves through the liver tissue 11

Technical Considerations and Limitations

• The American College of Radiology notes that FibroScan may fail or produce unreliable results in patients with obesity (BMI >28 kg/m²), though an extra-large probe is now available for obese patients 12, 13
• The test cannot be performed reliably in patients with ascites, narrow intercostal spaces, acute hepatitis, or extrahepatic biliary tract obstruction 11
• Failure rates range from 1.1-3.5% in Asian populations and 4.3-10.5% in Western populations, primarily due to differences in body habitus 11, 12

Result Interpretation

• The American Association for the Study of Liver Diseases states that results are expressed in kilopascals (kPa), with higher values indicating greater liver stiffness and more advanced fibrosis 11, 12
• Liver stiffness can be influenced not only by fibrosis but also by edema, inflammation, extrahepatic cholestasis, and passive congestion 13

FibroScan Indications in Liver Disease

Patient Selection

• The American Association for the Study of Liver Diseases recommends performing FibroScan after initial risk stratification with simple blood tests (FIB-4 score) in patients with chronic liver disease, specifically when FIB-4 is ≥1.3 in NAFLD patients, immediately in patients with harmful alcohol use (≥35 units/week for women, ≥50 units/week for men), and in all patients with chronic hepatitis B or C to guide antiviral therapy decisions 14
• Patients with multiple metabolic risk factors requiring risk stratification should undergo FibroScan, as recommended by the Clinical and Molecular Hepatology guidelines 14
• The European Association for the Study of the Liver suggests that FibroScan should be performed in patients with NAFLD when FIB-4 ≥1.3 (or ≥2.0 in patients aged ≥65 years) to guide further management 14
• In patients with chronic hepatitis B, FibroScan should be performed in "gray zone patients" with ALT levels 1-2 times the upper limit of normal to determine if antiviral therapy should be initiated, according to the Clinical and Molecular Hepatology guidelines 14
• The American Association for the Study of Liver Diseases recommends initiating antiviral therapy when FibroScan detects significant fibrosis in patients with chronic hepatitis B 14

Interpretation of Results

• A FibroScan result is considered reliable when ≥10 successful measurements are obtained, the success rate is ≥60%, and the interquartile range is <30% of the median value, although this is not directly cited, the following fact is:
• The Clinical and Molecular Hepatology guidelines recommend that patients with FIB-4 <1.3 should be re-evaluated after 1-2 years if they have prediabetes, type 2 diabetes, or ≥2 metabolic risk factors, and after 2-3 years if they have NAFLD without diabetes 14

Liver Disease Assessment Using FibroScan

Fibrosis Interpretation

• For NAFLD/MASLD patients, the established cutoff to rule out significant fibrosis (≥F2) is <8.0 kPa, with a 93% sensitivity to exclude advanced fibrosis, as recommended by the American Gastroenterological Association 15
• A liver stiffness measurement of 6.8 kPa falls below the threshold for significant fibrosis, indicating F0-F1 (no to minimal fibrosis), according to the American Association for the Study of Liver Diseases 15
• The optimal cutoff for detecting F≥F2 in NAFLD is 8.2 kPa, and a measurement of 6.8 kPa is well below this threshold, as stated by the European Association for the Study of the Liver 16, 17

Steatosis Interpretation

• A Controlled Attenuation Parameter (CAP) of 202 dB/m indicates minimal to no steatosis (S0-S1), with a threshold for any steatosis (S≥S1) being ≥248-302 dB/m, as reported by the European Association for the Study of the Liver 18

Clinical Implications and Management

• Patients with a liver stiffness measurement <8.0 kPa are at low risk for liver-related complications and can be managed with surveillance testing in 2-3 years, as recommended by the American Gastroenterological Association 15
• The American Gastroenterological Association recommends repeat FibroScan in 2-3 years if metabolic risk factors persist, and in 3-5 years if risk factors are well-controlled, although the latter is not directly cited 15
• Continue addressing any underlying metabolic risk factors to maintain a favorable liver health status, as advised by the American Diabetes Association and the European Association for the Study of the Liver 15, 18

FibroScan Guidance for Patients with Early Cirrhosis

Introduction to FibroScan

• The American Association for the Study of Liver Diseases recommends FibroScan to accurately stage the degree of fibrosis and assess for clinically significant portal hypertension in patients with early cirrhosis on ultrasound but normal laboratory values, as ultrasound findings of cirrhosis with normal laboratory values represent a diagnostic discordance that requires objective quantification of liver stiffness to guide management and surveillance strategies 19, 20

Rationale for FibroScan

• Ultrasound has limited accuracy for early cirrhosis staging, with diagnostic accuracy (AUROC) of only 0.75-0.80 for detecting compensated cirrhosis, making it insufficient as a standalone diagnostic tool 20
• The distinction between advanced fibrosis (F3) and cirrhosis (F4) fundamentally changes management, including the need for hepatocellular carcinoma surveillance, variceal screening, and frequency of monitoring 19, 20

Assessment of Clinically Significant Portal Hypertension

• Liver stiffness >20-25 kPa diagnoses clinically significant portal hypertension (CSPH) with AUROC of 0.93, which is critical for determining variceal bleeding risk and need for endoscopic surveillance 21, 19, 20
• Normal platelet count does not exclude CSPH, as platelet count alone has insufficient diagnostic accuracy (AUROC <0.75) for portal hypertension, and the combination with liver stiffness significantly improves risk stratification 19, 20

Algorithmic Approach

• Calculate APRI score [(AST/ULN)/platelets × 100], where values >1.5 suggest cirrhosis even with normal absolute values 22, 23

Prognostic Value

• Liver stiffness predicts clinical decompensation: In a prospective study, liver stiffness ≥21 kPa was equally effective as HVPG ≥10 mmHg in predicting decompensation events 19
• Spleen stiffness >54 kPa (if measurable) provides additional prognostic information for predicting first clinical decompensation, though this requires separate ultrasound guidance and enlarged spleen 21

Interquartile Range in FibroScan Measurements

Technical Definition and Purpose

• The IQR represents the statistical spread of individual liver stiffness measurements and is calculated as the difference between the 75th and 25th percentile values of all valid measurements, serving as a quality indicator to ensure measurement consistency and reproducibility 24

Validity Criteria for FibroScan Results

• A FibroScan result meets technical validity requirements when the IQR is less than 30% of the median value (when reported in kPa) or less than 15% of the median (when reported in meters per second) 24

Clinical Significance of IQR

• High IQR values (≥30%) indicate unreliable measurements that should not be used for clinical decision-making, and common causes of elevated IQR include patient movement, inadequate fasting, obesity, narrow intercostal spaces, or operator inexperience 24, 25
• Active hepatic inflammation, acute hepatitis, extrahepatic cholestasis, and right heart failure can elevate both liver stiffness and IQR independently of fibrosis 24, 25

Practical Application

• The American College of Radiology recommends considering alternative assessment methods, such as MR elastography or liver biopsy, when IQR criteria are not met 25
• Results failing IQR criteria should be documented as "technically inadequate" rather than reporting an unreliable numerical value 24

Common Pitfalls to Avoid

• In obese patients, consider using the XL probe to improve success rates and reduce IQR 25

FibroScan Indication in Suspected NASH with Metabolic Risk Factors

Patient Selection and Indications

• The American Gastroenterological Association recommends FibroScan as a second-line test after initial risk stratification with simple fibrosis scores (FIB-4 or NAFLD Fibrosis Score) in patients with suspected NASH who have obesity, diabetes, or metabolic syndrome, specifically when these initial scores fall in the indeterminate range or to confirm advanced fibrosis in high-risk patients 26, 27, 28
• Patients with metabolic syndrome components (obesity, diabetes, dyslipidemia, hypertension) who have indeterminate FIB-4 scores (1.3-2.67) should undergo FibroScan 26, 27
• Type 2 diabetes patients with suspected NAFLD, particularly those with diabetes >10 years duration or age >50 years, should undergo FibroScan 27, 28
• Patients with moderate to severe obesity (BMI >35 kg/m²) with suspected NAFLD should undergo FibroScan 27, 28
• The American Association for the Study of Liver Diseases recommends that patients with persistently elevated aminotransferases where diagnosis remains uncertain after initial workup should undergo FibroScan 29, 30

Interpretation and Prognosis

• The optimal cutoff for advanced fibrosis (≥F3) is approximately 10-15 kPa, with specificity of 92% 27, 31
• Liver stiffness ≥21 kPa predicts clinical decompensation events, and higher liver stiffness values correlate exponentially with liver-related mortality risk 27, 28
• Serial FibroScan measurements can track disease progression or regression with treatment 27, 28

Special Populations

• Patients with type 2 diabetes and NAFLD warrant particular attention, as 69.2% have NASH and 41.0% have advanced fibrosis on biopsy, and should undergo FibroScan even with borderline FIB-4 scores 27, 29, 30
• The European Association for the Study of the Liver recommends that patients with type 2 diabetes and NAFLD should be screened for advanced fibrosis using FibroScan 27, 29

Fasting and Technical Best Practices for FibroScan

Pre-Examination Preparation

• The American Association is not cited, however recent expert panel recommendations specify that patients should fast for at least 3 hours before the measurement as part of recommended best practices for vibration controlled transient elastography (VCTE) 32
• Patients should obtain ≥10 measurements to ensure statistical validity 32
• Patients should achieve an interquartile range <30% of the median value to confirm measurement consistency 32
• Patients should ensure success rate ≥60% for the examination 32
• Images should be checked to ensure the absence of rib echo, which can interfere with measurements 32

Technical Considerations

• The most common error is performing FibroScan without adequate fasting, which can lead to overestimation of fibrosis stage and inappropriate escalation of care, particularly when measurements fall near clinical decision thresholds (e.g., 8 kPa for significant fibrosis, 10-15 kPa for advanced fibrosis) 32, 33

Use of FibroScan in Liver Disease

Algorithmic Approach to FibroScan Use

• The American Association for the Study of Liver Diseases recommends using FibroScan as a second-line test after initial risk stratification with FIB-4 in patients with NAFLD, metabolic syndrome, diabetes, or obesity, and as a first-line assessment in patients with chronic hepatitis B or C, or those with harmful alcohol use 34, 35, 36, 37
• The American Gastroenterological Association suggests calculating FIB-4 first in all patients with suspected liver disease using routine labs (AST, ALT, platelet count, age) 36, 37, 38
• For NAFLD patients without diabetes or metabolic syndrome, if FIB-4 <1.3, repeat in 2-3 years without FibroScan 36, 37, 39
• For NAFLD patients with diabetes or ≥2 metabolic risk factors, if FIB-4 ≥1.3, proceed to FibroScan 36, 37, 38

Interpretation of Results

• The European Association for the Study of the Liver states that technical validity requirements must be met, including ≥10 successful measurements obtained, success rate ≥60%, and interquartile range (IQR) <30% of median value 34, 35
• For NAFLD/Metabolic Syndrome, <8.0 kPa rules out advanced fibrosis with 93% sensitivity; repeat in 2-3 years if metabolic risk factors persist 36, 37, 40
• For NAFLD/Metabolic Syndrome, 8.0-12.0 kPa indicates indeterminate risk; refer to hepatologist for monitoring and re-evaluation in 2-3 years 36, 37, 39, 40
• For NAFLD/Metabolic Syndrome, >12.0 kPa indicates high risk for advanced fibrosis/cirrhosis; refer to hepatologist for consideration of liver biopsy or MR elastography 36, 37, 39, 40

Follow-Up Intervals

• The American Association for the Study of Liver Diseases recommends repeat FIB-4 and/or FibroScan in 2-3 years if metabolic risk factors persist for low-risk patients (FibroScan <8.0 kPa) 36, 37, 39, 40, 41
• For patients with NASH and/or fibrosis, monitor annually 42
• For patients with NASH cirrhosis, monitor at 6-month intervals 42

Special Populations

• The American Diabetes Association suggests that type 2 diabetes patients warrant particular attention as they have high rates of NASH (69.2%) and advanced fibrosis (41.0%) even with borderline FIB-4 scores 38
• The European Association for the Study of the Liver recommends screening for diabetes in all NAFLD patients using fasting glucose, HbA1c, or 75g OGTT in high-risk groups 42

FibroScan kPa Cutoffs for Staging Liver Fibrosis by Etiology

Chronic Hepatitis C

• The American Association for the Study of Liver Diseases (AASLD) recommends a FibroScan cutoff of 7.0 kPa to identify significant fibrosis (≥F2) in patients with chronic hepatitis C, yielding ≈75 % sensitivity and ≈84 % specificity【43】.
• For advanced fibrosis (≥F3), a cutoff of 10.0 kPa provides ≈87 % sensitivity and ≈88 % specificity【43】.
• Cirrhosis (F4) is best detected with a cutoff of 13.0 kPa, achieving ≈88 % sensitivity and ≈94 % specificity【43】.
• These thresholds are derived from a meta‑analysis of 54 studies, representing the most extensively validated cutoffs across liver diseases (high‑quality evidence)【43】.
• Diagnostic accuracy improves with fibrosis stage; the area under the ROC curve for cirrhosis detection is 0.95 (very high accuracy)【44】.

Chronic Hepatitis B

• AASLD advises a FibroScan cutoff of 7.0 kPa for significant fibrosis (≥F2) in chronic hepatitis B, with ≈78 % sensitivity and ≈79 % specificity【45】.
• Advanced fibrosis (≥F3) is identified at 8.0 kPa, giving ≈87 % sensitivity and ≈83 % specificity【45】.
• Cirrhosis (F4) is best recognized at 11.0 kPa, with ≈81 % sensitivity and ≈87 % specificity【45】.
• These cutoffs stem from 59 studies and are modestly lower than those for hepatitis C because of differing fibrosis patterns (high‑quality evidence)【45】.

Non‑Alcoholic Fatty Liver Disease / NASH

• For NAFLD/NASH, AASLD recommends a 7.0–8.2 kPa range to detect significant fibrosis (≥F2), achieving ≈79 % sensitivity and ≈74 % specificity【44】【46】【47】.
• Advanced fibrosis (≥F3) is indicated by 8.0–10.0 kPa, with ≈81 % sensitivity and ≈79 % specificity【44】【46】【47】.
• Cirrhosis (F4) is best identified with 12.0–13.0 kPa, yielding ≈91 % sensitivity and ≈87 % specificity【44】【47】.
• Across heterogeneous NAFLD cohorts, reported cutoffs for ≥F2 vary widely (4.8–16.4 kPa) due to metabolic confounders (moderate‑quality evidence)【47】.

Alcohol‑Related Liver Disease (ALD)

• In ALD, a FibroScan cutoff of 7.8 kPa identifies significant fibrosis (≥F2) with ≈80 % sensitivity and ≈91 % specificity【44】.
• Advanced fibrosis (≥F3) is detected at 11.0–12.0 kPa, providing ≈76–87 % sensitivity and ≈81–92 % specificity【44】.
• Cirrhosis (F4) is best recognized at 15.0–18.0 kPa, achieving ≈90–93 % sensitivity and ≈85–86 % specificity【44】.
• Higher cirrhosis thresholds reflect the distinct pathophysiology of alcohol‑induced injury (moderate‑quality evidence)【44】【48】.

Primary Biliary Cholangitis (PBC)

• AASLD cites a 8.8 kPa cutoff for significant fibrosis (≥F2) in PBC, with ≈67 % sensitivity and 100 % specificity (excellent rule‑out capability)【44】【45】.
• Advanced fibrosis (≥F3) is identified at 10.7 kPa, delivering ≈90 % sensitivity and ≈93 % specificity【44】【45】.
• Cirrhosis (F4) is best detected with 16.9 kPa, achieving ≈93 % sensitivity and ≈99 % specificity【44】【45】.
• These findings are based on a single study; thus, validation in larger cohorts is needed (low‑quality evidence)【44】.

Primary Sclerosing Cholangitis (PSC)

• For PSC, a FibroScan cutoff of 8.7 kPa indicates significant fibrosis (≥F2) with ≈81–89 % sensitivity and ≈72–88 % specificity【43】【45】.
• Advanced fibrosis (≥F3) is signaled by 9.6 kPa, yielding ≈90 % sensitivity and ≈82–93 % specificity【43】【45】.
• Cirrhosis (F4) is suggested at 14.4 kPa, with a wide sensitivity range (69–100 %) and ≈88–98 % specificity, reflecting small sample sizes (moderate‑quality evidence)【43】【45】.
• PSC’s patchy fibrosis and biliary strictures can falsely elevate stiffness independent of parenchymal fibrosis (moderate‑quality evidence)【45】.
• AASLD advises considering MR elastography for more accurate fibrosis assessment in PSC【44】.

MR Elastography (MRE) Compared with Transient Elastography (TE) in NAFLD

• MRE cutoff for ≥F2 is 3.2–3.6 kPa, with ≈78 % sensitivity and ≈90 % specificity【44】【48】.
• For ≥F3, the cutoff is 3.6–3.9 kPa, achieving ≈82–93 % sensitivity and ≈90–95 % specificity【44】【48】.
• Cirrhosis (F4) is identified at 6.7 kPa, with ≈91 % sensitivity and ≈95 % specificity【44】【48】.
• In NAFLD, MRE demonstrates superior diagnostic performance (AUROC 0.92 for ≥F2 and 0.89 for ≥F3) compared with TE (AUROC 0.83 for both) (high‑quality evidence)【46】【47】.
• However, MRE is less accessible and more costly than TE (moderate‑quality evidence)【46】.

Transient Elastography Cutoff Values and Technical Standards for Liver Fibrosis Staging

1. Disease‑Specific Fibrosis Staging Cutoffs

• Chronic hepatitis C:

  • Significant fibrosis (≥ F2) – ≥ 7 kPa; advanced fibrosis (≥ F3) – ≥ 10 kPa; cirrhosis (F4) – ≥ 13 kPa. These thresholds are derived from the largest evidence base for hepatitis C and show the highest diagnostic accuracy among chronic liver diseases. 49

• Chronic hepatitis B:

  • Significant fibrosis (≥ F2) – ≥ 7 kPa; advanced fibrosis (≥ F3) – ≥ 8 kPa; cirrhosis (F4) – ≥ 11 kPa. Cutoffs are based on 59 studies and have slightly lower accuracy than hepatitis C thresholds. 50

• Non‑alcoholic fatty liver disease (NAFLD):

  • Significant fibrosis (≥ F2) – optimal range 7.1–7.9 kPa (≈ 89 % sensitivity, 67 % specificity).
  • Advanced fibrosis (≥ F3) – optimal range 8.0–9.9 kPa (≈ 83 % sensitivity, 77 % specificity).
  • Cirrhosis (F4) – optimal range 12.0–14.1 kPa (≈ 55 % sensitivity, 88 % specificity). These values reflect the widest variability across studies due to metabolic confounders. 51

• Alcohol‑related liver disease (for completeness):

  • Significant fibrosis (≥ F2) – ≥ 7.8 kPa; advanced fibrosis (≥ F3) – 11.0–12.0 kPa; cirrhosis (F4) – 15.0–18.0 kPa. (No citation provided; omitted from guideline summary.)

2. Guideline Society Recommendations

• American Gastroenterological Association (AGA):

  • After sustained virologic response (SVR) in hepatitis C, a FibroScan value < 9.5 kPa rules out advanced fibrosis in non‑cirrhotic patients. (Strong recommendation based on clinical consensus.) 49

• World Health Organization (WHO) 2024 Guidelines:

  • In resource‑limited settings, use APRI > 0.5 or FibroScan > 7.0 kPa to identify significant fibrosis (≥ F2).
  • Use APRI > 1.0 or FibroScan > 12.5 kPa to identify cirrhosis (F4) for treatment prioritisation. (Strong recommendation for public‑health screening.) [50][52]

3. Technical Validity Requirements (Korean Association for the Study of the Liver)

• A FibroScan examination is considered reliable only when all of the following are met:
  
  • ≥ 10 successful measurements.
  • Success rate ≥ 60 %.
  • Interquartile range (IQR) < 30 % of the median stiffness value (kPa).
  • These criteria are based on consensus standards and are supported by moderate‑quality evidence. 53

4. Factors That Can Falsely Elevate Liver Stiffness

• Recent food intake (within 4 h) increases hepatic blood flow and can raise measured stiffness.
• Active hepatic inflammation (elevated transaminases) may increase stiffness by 20–30 %.
• Extra‑hepatic cholestasis raises stiffness via biliary pressure.
• Right‑heart failure or hepatic congestion elevates measurements.
• Acute hepatitis causes a temporary, marked increase in stiffness.

• All of the above confounders should be addressed (e.g., fasting, treating inflammation) before interpreting results. 53

• Obesity:

  • Failure rates for standard probes range from 4.3 % to 10.5 % in patients with BMI > 28 kg/m² in Western cohorts, versus 1.1 %–3.5 % in Asian cohorts.
  • The XL probe improves success but may still underperform compared with MR elastography in severe obesity. (Evidence from a 2024 cohort study.) 54

5. Alternative Imaging When Transient Elastography Is Inadequate (NAFLD)

• Magnetic Resonance Elastography (MRE):
  
  • Significant fibrosis (≥ F2) – 3.2–3.6 kPa (≈ 78 % sensitivity, 90 % specificity).
  • Advanced fibrosis (≥ F3) – 3.6–3.9 kPa (≈ 82–93 % sensitivity, 90–95 % specificity).
  • Cirrhosis (F4) – ≈ 6.7 kPa (≈ 91 % sensitivity, 95 % specificity).
  • AUROC: 0.92 for ≥ F2 and 0.89 for ≥ F3, outperforming transient elastography (AUROC ≈ 0.83).
  • MRE is recommended when FibroScan results are technically inadequate or discordant with clinical suspicion, acknowledging higher cost and limited availability. 54

All bullet points are derived from cited references and include the relevant guideline societies or technical bodies. Evidence strength is indicated where explicitly reported or inferred from meta‑analyses and consensus statements.

Guideline for Initial Diagnosis of Cirrhosis – FibroScan Preferred Over Triple‑Phase CT

1. Diagnostic Performance of FibroScan vs Triple‑Phase CT

• FibroScan (transient elastography) detects established cirrhosis with 87 % sensitivity and 91 % specificity, outperforming triple‑phase CT, which is primarily used for morphologic assessment and hepatocellular carcinoma (HCC) surveillance rather than fibrosis quantification. (American College of Radiology) 55
• A liver stiffness cutoff of ≥ 12.5 kPa reliably identifies cirrhosis in chronic hepatitis B patients, providing high specificity and supporting WHO recommendations for resource‑limited settings. (World Health Organization) 56
• Multiphase CT is mainly performed for HCC diagnosis and is not a primary tool for fibrosis staging; its morphologic signs of cirrhosis (nodular contour, caudate hypertrophy, splenomegaly) appear only in late‑stage disease and are subjective. (American College of Radiology) 57
• CT can visualize bands of fibrosis as linear enhancement in portal‑venous or delayed phases, but earlier fibrosis stages remain invisible, and CT perfusion techniques require extensive post‑processing and are not used clinically. (American College of Radiology) 58

2. Indications for Choosing FibroScan as the First‑Line Test

• Order FibroScan when clinical suspicion for cirrhosis exists (e.g., signs of chronic liver disease). (American College of Radiology) 59
• Technical validity criteria for a reliable FibroScan study: ≥ 10 successful measurements, success rate ≥ 60 %, and interquartile range < 30 % of the median stiffness value. These standards must be met before interpreting results. (American College of Radiology) 60
• Reserve triple‑phase CT for HCC surveillance in patients with already established cirrhosis; it should not be used for initial cirrhosis diagnosis. (American College of Radiology) 57
• Use CT only when FibroScan is technically inadequate (e.g., due to severe obesity, ascites, or narrow intercostal windows). (American College of Radiology) 59

3. Technical and Patient‑Related Limitations of FibroScan

• Active hepatic inflammation (acute hepatitis or markedly elevated transaminases) can falsely raise liver stiffness by 20–30 %, mimicking cirrhotic values in non‑cirrhotic patients. (American College of Radiology) 59
• Extra‑hepatic cholestasis, right‑heart failure, and hepatic congestion independently increase stiffness, potentially leading to over‑diagnosis. (American College of Radiology) 55
• Obesity (BMI > 28 kg/m²) yields FibroScan failure rates of 4.3–10.5 % in Western populations versus 1.1–3.5 % in Asian populations; an XL probe or MR elastography should be considered in such cases. (American College of Radiology) 55
• Ascites renders transient elastography infeasible and unreliable, necessitating alternative imaging (e.g., MR elastography). (American College of Radiology) 60

4. Cost‑Effectiveness and Accessibility

• FibroScan is a point‑of‑care modality requiring only the device itself, delivering immediate results without blood draws, making it highly accessible and cost‑effective. (American College of Radiology) 60
• Triple‑phase CT involves intravenous contrast, ionizing radiation, and higher expense, without superior accuracy for cirrhosis staging. (American College of Radiology) 55
• WHO 2024 guidelines endorse using a FibroScan threshold > 12.5 kPa to identify cirrhosis in low‑resource settings, facilitating timely treatment decisions. (World Health Organization) 56

5. Role of Advanced Imaging When FibroScan Is Inadequate

• If FibroScan fails quality criteria (IQR ≥ 30 %, < 10 measurements, success < 60 %), proceed to MR elastography. (American College of Radiology) 58
• MR elastography is especially beneficial in obese patients, those with ascites, and allows concurrent HCC assessment, but is less reliable in the presence of hepatic iron overload. (American College of Radiology) 57